Catherine V. Bird
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
A phase 2 uncontrolled, open-label study of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine) in patients with treatment-resistant depression.
Journal: Journal of psychopharmacology (Oxford, England)
Published: February 27, 2026
Effects of psilocybin on personality, psychiatric symptoms, and values: Exploring mediating effects of the acute psychedelic experience.
Journal: Journal of psychopharmacology (Oxford, England)
Published: January 27, 2026
Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial.
Journal: Nature medicine
Published: January 21, 2026
How to set up a psychedelic study: Unique considerations for research involving human participants.
Journal: Neuroscience and biobehavioral reviews
Published: November 28, 2025
Probing the functional magnetic resonance imaging response to psilocybin in functional neurological disorder (PsiFUND): study protocol.
Journal: Wellcome open research
Published: October 07, 2024
Low-dose psilocybin in short-lasting unilateral neuralgiform headache attacks: results from an open-label phase Ib ascending dose study.
Journal: Headache
Published: November 13, 2023
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.
Journal: The New England journal of medicine
Published: November 02, 2022
The CannTeen Study: Cannabis use disorder, depression, anxiety, and psychotic-like symptoms in adolescent and adult cannabis users and age-matched controls.
Journal: Journal of psychopharmacology (Oxford, England)
Published: June 30, 2022
Springtime for psychopharmacology.
Journal: Journal of psychopharmacology (Oxford, England)
Published: March 07, 2022
The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation.
Journal: Journal of psychopharmacology (Oxford, England)
Published: January 29, 2022
Psilocybin-assisted therapy for the treatment of resistant major depressive disorder (PsiDeR): protocol for a randomised, placebo-controlled feasibility trial.
Journal: BMJ open
Published: December 02, 2021
Psilocybin and MDMA for the treatment of trauma-related psychopathology.
Journal: International review of psychiatry (Abingdon, England)
Published: June 14, 2021
Last Updated: 09/26/2026